Nygaard T G
Department of Neurology, Columbia University, New York, USA.
Curr Opin Neurol. 1995 Aug;8(4):310-3. doi: 10.1097/00019052-199508000-00011.
The past 18 months have seen significant advances in our understanding of dopa(dihydroxyphenylalanine)-responsive dystonia. Clinical investigations have broadened the spectrum of disease with particular attention manifestations in infancy. Pathophysiological investigations have revealed features that distinguish dopa-responsive dystonia from childhood-onset parkinsonism. A pathological study has confirmed the 'developmental' nature of the disease. Finally, mutations causing the autosomal dominant form of dopa-responsive dystonia have been identified in the gene coding for GTP cyclohydrolase I. Mutations in tyrosine hydroxylase have been identified in two brothers and put forward as evidence of an autosomal recessive form of the disease.
在过去的18个月里,我们对多巴(二羟基苯丙氨酸)反应性肌张力障碍的认识取得了重大进展。临床研究拓宽了疾病谱,特别关注婴儿期的表现。病理生理学研究揭示了多巴反应性肌张力障碍与儿童期帕金森病的区别特征。一项病理学研究证实了该疾病的“发育性”本质。最后,在编码GTP环化水解酶I的基因中发现了导致常染色体显性形式多巴反应性肌张力障碍的突变。在两名兄弟中发现了酪氨酸羟化酶的突变,并提出这是该疾病常染色体隐性形式的证据。